[1] Fan CY,Lee WT,Hsu TC,et al.Effect of chlorhexidine bath-ing on colonization or infection with Acinetobacter baumannii:a systematic review and meta-analysis[J]. J Hosp Infect,2019, 103(3):284-292. [2] Garnacho-Montero J,Timsit JF.Managing Acinetobacter bauman-nii infections[J]. Curr Opin Infect Dis,2019,32(1):69-76. [3] 汪静,何樱瑛,张颖华,等. 上海闵行区某医疗机构鲍曼不动杆菌污染分析[J]. 中国卫生检验杂志,2021,31(9):1120-1122, 1126. Wang J,He YY,Zhang YH,et al.Analysis of Acinetobacter baumannii contamination in a medical institution in Minhang District[J]. Chin J Heal Lab Technol,2021,31(9):1120-1122, 1126. [4] 毛劲松,朱莺莺,吴海燕,等. 从可视化分析看我国重症医学科多重耐药菌研究热点[J]. 中华危重病急救医学,2021(5):587-592. Mao JS,Zhu YY,Wu HY,et al.Visual analysis of research on multidrug-resistant bacteria in intensive care unit in China[J]. Chin Crit Care Med,2021(5):587-592. [5] 蒋钟吉,吴劲松,刘雪燕,等. 深圳某三甲医院2019年ICU病原菌分布及耐药性分析[J]. 中国抗生素杂志,2021,46(8):795-799. Jiang ZJ,Wu JS,Liu XY,et al.Distribution and drug resistance of pathogens in ICU of a major hospital in Shenzhen in 2019[J]. Chin J Antibiot,2021,46(8):795-799. [6] 胡付品,郭燕,朱德妹,等. 2018年CHINET中国细菌耐药性监测[J]. 中国感染与化疗杂志,2020,20(1):1-10. Hu FP,Guo Y,Zhu DM,et al.CHINET surveillance of bacterial resistance in China:2018 report[J]. Chin J Infect Chemother,2020,20(1):1-10. [7] Nasiri MJ,Zamani S,Fardsanei F,et al.Prevalence and mechanisms of carbapenem resistance in Acinetobacter baumannii:a comprehensive systematic review of cross-sectional studies from Iran[J]. Microb Drug Resist,2020,26(3):270-283. [8] 陈安林,陈娅,陈泽慧,等. 医院感染多重耐药鲍曼不动杆菌患者死亡危险因素的Meta分析[J]. 中国感染控制杂志,2019,18(1):53-58. Chen AL,Chen Y,Chen ZH,et al.Meta-analysis on risk factors for death in patients with healthcare-associated infection caused by multidrug-resistant Acinetobacter baumannii[J]. Chin J Infect Control,2019,18(1):53-58. [9] 祝司霞,庞载元. 泛耐药鲍曼不动杆菌呼吸道定植如何管理?[J]. 中国全科医学,2019,22(27):3286-3291. Zhu SX,Pang ZY.Management of extensively drug-resistant Aci-netobacter baumannii colonizes in the respiratory tract[J]. Chin Gen Pract,2019,22(27):3286-3291. [10] 周华,周建英,俞云松. 中国鲍曼不动杆菌感染诊治与防控专家共识解读[J]. 中国循证医学杂志,2016,16(1):26-29. Zhou H,Zhou JY,Yu YS.The interpretation of Chinese expert consensus for the diagnosis,treatment,prevention and control of acinetobacter baumannii infection[J]. Chin J Evid Based Med,2016,16(1):26-29. [11] Magiorakos AP,Srinivasan A,Carey RB,et al.Multidrug-resistant,extensively drug-resistant and pandrug-resistant bacteria:an international expert proposal for interim standard definitions for acquired resistance[J]. Clin Microbiol Infect,2012, 18(3):268-281. [12] Peleg AY,Seifert H,Paterson DL.Acinetobacter baumannii:emer-gence of a successful pathogen[J]. Clin Microbiol Rev,2008, 21(3):538-582. [13] Horan TC,Andrus M,Dudeck MA.CDC/NHSN surveillance de-finition of health care-associated infection and criteria for specific types of infections in the acute care setting[J]. Am J Infect Control,2008,36(5):309-332. [14] 陈悦,陈超美,刘则渊,等. CiteSpace知识图谱的方法论功能[J]. 科学学研究,2015,33(2):242-253. Chen Y,Chen CM,Liu ZY,et al.The methodology function of CiteSpace mapping knowledge domains[J]. Stud Sci Sci,2015, 33(2):242-253. [15] 胡付品,朱德妹,汪复,等. 2013年中国CHINET细菌耐药性监测[J]. 中国感染与化疗杂志,2014,14(5):365-374. Hu FP,Zhu DM,Wang F,et al.CHINET 2013 surveillance of bacterial resistance in China[J]. Chin J Infect Chemother,2014,14(5):365-374. [16] 陈佰义,何礼贤,胡必杰,等. 中国鲍曼不动杆菌感染诊治与防控专家共识[J]. 中国医药科学,2012,2(8):3-8. Chen BY,He LX,Hu BJ,et al.Expert consensus on diagnosis,treatment and prevention and control of Acinetobacter baumannii infection in China[J]. China Med Pharm,2012,2(8):3-8. [17] 孙世鹏,旷南岳,漆新文. 多重耐药鲍曼不动杆菌感染相关危险因素及耐药性分析[J]. 临床合理用药杂志,2018,11(1):7-8,11. Sun SP,Kuang NY,Qi XW.Multiple drug resistant acinetobacter baumannii infection associated risk factors and drug resistance analysis[J]. Chin J Clin Ration Drug Use,2018,11(1):7-8,11. [18] 王莉,张桂侠,卢晓娥. 某院重症医学科患者多重耐药鲍曼不动杆菌医院感染危险因素分析[J]. 中国消毒学杂志,2018,35(6):478-480. Wang L,Zhang GX,Lu XE.Risk factors for nosocomial infection of multidrug-resistant Acinetobacter baumannii in a hospital[J]. Chin J Disinfect,2018,35(6):478-480. [19] 胡旻昊,钱妙瑾,杨忠慧. ICU患者多重耐药鲍曼不动杆菌感染的危险因素及其耐药性分析[J]. 抗感染药学,2018,15(6):948-953. Hu MH,Qian MJ,Yang ZH.Analysis on risk factors and drug resistance infected by multidrug-resistant acinetobacter baumannii in ICU patients[J]. Anti Infect Pharm,2018,15(6):948-953. [20] 王瑞峰,曹大伟,张新日. 我国耐碳青霉烯类鲍曼不动杆菌医院感染危险因素的Meta分析[J]. 安徽医药,2020,24(11):2121-2127. Wang RF,Cao DW,Zhang XR.A meta-analysis of risk factors for nosocomial infection of carbapenems resistant acinetobacter baumannii in China[J]. Anhui Med Pharm J,2020,24(11):2121-2127. [21] 李娜,黄艳芳,唐喻莹,等. 多重耐药鲍曼不动杆菌医院感染危险因素荟萃分析[J]. 中国感染控制杂志,2017,16(2):115-120. Li N,Huang YF,Tang YY,et al.Meta-analysis on risk factors for healthcare-associated infection with multidrug-resistant Acinetobacter baumannii[J]. Chin J Infect Control,2017,16(2):115-120. [22] Ben-Chetrit E,Wiener-Well Y,Lesho E,et al.An intervention to control an ICU outbreak of carbapenem-resistant Acinetobacter baumannii:long-term impact for the ICU and hospital[J]. Crit Care,2018,22(1):319. [23] 乔甫,宗志勇. 世界卫生组织《医疗机构耐碳青霉烯的肠杆菌科细菌、铜绿假单胞菌和鲍曼不动杆菌防控指南》介绍[J]. 华西医学,2018,33(3):259-263. Qiao F,Zong ZY.Interpretation of guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae,acinetobacter baumannii and pseudomonas aeruginosa in health care facilities[J]. West China Med J,2018,33(3):259-263. [24] 李阳洋,邵小平,蒋卓娟,等. ICU环境感染预防及管理的循证护理实践[J]. 中华急危重症护理杂志,2020,1(5):459-463. Li YY,Shao XP,Jiang ZJ,et al.Evidence-based nursing practice for the prevention and management of environmental infection in ICU[J]. Chin J Emerg Crit Care Nurs,2020,1(5):459-463. [25] 曾妃,封秀琴,赵锐祎,等. 群体大面积烧爆复合伤患者单元化感染防控的实践及成效[J]. 中华急危重症护理杂志,2021,2(2):123-126. Zeng F,Feng XQ,Zhao RY,et al.The practice and effect of unit-based infection prevention and control in a group of patients with massive burn and explosion combined injury[J]. Chin J Emerg Crit Care Nurs,2021,2(2):123-126. [26] 张燕红,胡静,顾莺,等. 危重症患儿机械通气下口腔护理频率的研究[J]. 中华急危重症护理杂志,2020,1(3):208-211. Zhang YH,Hu J,Gu Y,et al.Research on the frequency of oral care in critical children with mechanical ventilation[J]. Chin J Emerg Crit Care Nurs,2020,1(3):208-211. |